Professional Media briefs

Share this article:
PDR Network has named Richard Altus company president. He joins PDR from ImpactRx, where he was president and CEO from 2006 to August 2011. At PDR, Altus will supervise overall operations and help expand the company's digital product offerings.

Global medical publisher Elsevier has launched an iPad edition of the European Journal of Cancer (EJC), beginning with the September 2011 issue. All 18 annual issues of the EJC are now offered via the EJC App in the App Store.

The American College of Cardiology (ACC) and The American Journal of Managed Care (AJMC) have launched the Community on Payment Innovations, a website to advance the payment-reform debate and promote an environment in which patients can access high-quality, affordable care.

AF Stat: A Call to Action for Atrial Fibrillation, has issued updates for its free smartphone app and desktop widget, AFib Educator, which helps HCPs better explain atrial fibrillation to their patients.

Publicis Healthware International (PHI) and dotSUB have launched, a video portal that allows users to access quality healthcare and wellness content from sources around the globe.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?